ϳԹ Announces Successful Asset Purchase Agreement with SQZ Biotechnologies Company
Major asset acquisition from a U.S.-based company marks another milestone for Canada’s largest biotechnology company
Vancouver, BC, February 29, 2024 – ϳԹ is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation).
This transaction, which was approved by SQZ shareholders today, marks another significant milestone for ϳԹ, Canada’s largest biotechnology company.
“This exciting acquisition means that ϳԹ’s own instruments will have the potential to be used in the delivery of cell therapies to cure diseases, like cancer,” said Dr. Allen Eaves, President and CEO, ϳԹ. “This transaction is an important achievement for ϳԹ and a win for Canada’s economy and life sciences sector as it will support the development of innovative cell therapies.”
This is ϳԹ’s second acquisition in the biotechnology sector this year. In January 2024, ϳԹ purchased Propagenix Inc., a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.
With the approval of the SQZ transaction, ϳԹ has acquired substantially all of SQZ’s assets including its entire portfolio of over 400 patents and trademarks, other intellectual property such as copyrights and trade secrets, proprietary equipment, and its head license with the Massachusetts Institute of Technology.
“Since our inception, SQZ’s vision has been to transform patient outcomes by helping to make life-changing cell therapies widely and rapidly accessible, and we are confident that ϳԹ can drive this important ambition toward a global reality,” said Dr. Howard Bernstein, Interim CEO, SQZ Biotechnologies.
In 2020, ϳԹ exclusively licensed the rights to SQZ’s patent portfolio to develop and commercialize the CellPore™ Transfection System and associated CellPore™ Transfection Kits in the research use market. With this new agreement, ϳԹ will be able to exclusively commercialize these products for use in all markets, including clinical applications.
“Over our 30-year history, ϳԹ has proudly developed the products required for scientific research around the world, and now with SQZ’s technology and proprietary expertise, we are poised to increase our offering even further into the clinical space and ultimately help patients everywhere,” said Dr. Eaves.
About ϳԹ
supports life sciences research with more than 2,500 specialized reagents, tools, and services. ϳԹ offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
Media Contact
For more information and to arrange an interview, contact:
Ryan-Sang Lee
Director, Corporate Communications and Media Relations, ϳԹ
public.relations@stemcell.com
Latest ϳԹ News
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
